The following table provides information about the project.
EBERHARD KARLS UNIVERSITAET TUEBINGEN
|Coordinator Country||Germany [DE]|
|Total cost||6˙307˙599 €|
|EC max contribution||5˙994˙030 € (95%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||coordinator||1˙892˙049.00|
|2||ACE PHARMACEUTICALS BV||NL (ZEEWOLDE)||participant||1˙461˙536.00|
|3||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||participant||634˙710.00|
|4||FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA||ES (VALENCIA)||participant||233˙464.00|
|5||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||210˙313.00|
|6||OSLO UNIVERSITETSSYKEHUS HF||NO (OSLO)||participant||207˙489.00|
|7||UNIVERSITA DEGLI STUDI DI UDINE||IT (UDINE)||participant||196˙432.00|
|8||HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ||FI (HELSINKI)||participant||179˙550.00|
|9||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||171˙756.00|
|10||UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU||PL (POZNAN)||participant||159˙576.00|
|11||UNIVERSIDADE DO PORTO||PT (PORTO)||participant||143˙842.00|
|12||OSTRAVSKA UNIVERZITA||CZ (OSTRAVA)||participant||140˙624.00|
|13||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||participant||136˙384.00|
|14||HELSINGIN YLIOPISTO||FI (HELSINGIN YLIOPISTO)||participant||127˙875.00|
|15||TARTU ULIKOOL||EE (TARTU)||participant||98˙426.00|
|16||UNIVERSITAT ZURICH||CH (ZURICH)||participant||0.00|
Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe. Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal intensive care, 45-50% of affected children die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective interventions, beside hypothermia, are warranted to further improve their outcome. Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and brain damage in experimental, animal, and early human studies of ischemia and reperfusion. This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants with HIE in addition to hypothermic treatment. Beyond this primary objective, the project will provide information on the effect of hypothermia on pharmacokinetics of drugs with a similar metabolism as allopurinol in neonates. Furthermore it will give the opportunity to further develop and validate biomarkers for neonatal brain injury using advanced magnetic resonance imaging, biochemistry, and electroencephalogramms, which will then be available for future studies testing neuroprotective interventions. Finally, this trial will extend our knowledge about incidence of and risk factors for perinatal asphyxia and HIE possibly enabling generation of more preventive strategies for the future.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALBINO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ALBINO" are provided by the European Opendata Portal: CORDIS opendata.
EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPANDRead More
DualDur: A Disruptive Diagnostic Technology that Enables for the First Time an Early and Accurate Diagnosis of the tick-borne Lyme Disease.Read More
Detecting serious diseases due to abnormal cellular energeticsRead More